Drug Profile
Gefitinib - AstraZeneca
Alternative Names: Iressa; ZD-1839Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Hutchison MediPharma; Massachusetts General Hospital; MedImmune; University of Texas M. D. Anderson Cancer Center
- Class Amines; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Morpholines; Phenyl ethers; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Salivary gland cancer
- No development reported Head and neck cancer
- Discontinued Bladder cancer; Brain metastases; Breast cancer; Colorectal cancer; Glioblastoma; Renal cell carcinoma; Thyroid cancer
Most Recent Events
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
- 31 Dec 2020 AstraZeneca completes a phase III clinical trial for Non-small cell lung cancer (Adjuvant therapy) in Japan (PO, Tablet) (UMIN000006252)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Newly diagnosed) in USA (PO, Tablet)